Trial record 16 of 17 for:    Sandhoff Disease

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (UCBT-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00654433
Recruitment Status : Terminated (Terminated - Sponsor Decision)
First Posted : April 8, 2008
Last Update Posted : July 8, 2014
Information provided by (Responsible Party):

April 3, 2008
April 8, 2008
July 8, 2014
March 2008
July 2011   (Final data collection date for primary outcome measure)
To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inherited metabolic diseases [ Time Frame: 180 Days ]
Same as current
Complete list of historical versions of study NCT00654433 on Archive Site
  • To assess the efficacy of ALD-101 in accelerating neutrophil engraftment [ Time Frame: 180 Days ]
  • To assess the safety of adjuvant therapy of ALD-101 in infusional toxicity, adverse events, and primary graft failure. [ Time Frame: 180 Days ]
Same as current
Not Provided
Not Provided
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism

Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion.

The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.

Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the child's normal cells including their bone marrow (which forms blood cells) in order to prepare their body for the umbilical cord blood transplant. The cord blood transplant is intended to rescue your child's bone marrow from the bad effects of the procedure. The child will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell called ALD-101.

The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly after transplant. This would shorten the period of time that the transplanted subject would be at risk for infection and bleeding and would also decrease the number of red blood cell and platelet transfusions needed.

ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with genetic diseases and malignancy in one previous clinical study that is on-going.

The main purpose of this research study is to test whether a portion of cord blood cells that have been separated from a cord blood unit (ALD-101) will increase the speed at which normal levels of circulating blood cells are re-established after transplant. This is the experimental part of this study. ALD-101 is also being tested to see if it is safe.

Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Inherited Metabolic Diseases
  • Lysosomal Storage Disorders
  • Peroxisomal Storage Diseases
  • Inborn Errors of Metabolism
  • Mucopolysaccharidosis
Biological: ALD-101
A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
Experimental: I
Intervention: Biological: ALD-101

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • confirmed diagnosis of inherited metabolic diseases; including the following:

    • Hurler Syndrome (MPS I)
    • Hurler-Scheie Syndrome
    • Hunter Syndrome (MPS II)
    • Sanfilippo Syndrome A and B(MPS III)
    • Maroteaux-Lamy Syndrome (MPS VI)
    • Krabbe Disease (Globoid Leukodystrophy)
    • Metachromatic Leukodystrophy (MLD)
    • Adrenoleukodystrophy (ALD and AMN)
    • Sandhoff Disease
    • Tay Sachs Disease
    • Pelizaeus Merzbacher (PMD)
    • Niemann-Pick Disease
    • Alpha-mannosidosis
    • I-Cell Disease (ML II)
    • Fucosidosis
    • GM I Gangliosidosis
    • Canavan Disease
  • must be <16 years of age at the time of study enrollment
  • must have a good performance status (Lansky ≥80%)
  • must have adequate function of other organ systems including: kidney, liver, heart and lungs
  • must have given valid written informed consent
  • must have a minimum life expectancy of at least 6 months
  • must be determined to be a good candidate for a standard umbilical cord blood transplant
  • must have an IQ >70 or if too young for IQ testing the potential to reach this endpoint by age 5

Exclusion Criteria:

  • HIV, Hepatitis B and/or Hepatitis C positive
  • concurrently involved in any other clinical study that affects engraftment or immune reconstitution
  • uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain stem involvement
  • uncontrolled infections
  • prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12 months of enrollment
Sexes Eligible for Study: All
up to 16 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Study Director: James Hinson, MD Aldagen
Principal Investigator: Joanne Kurtzberg, MD Duke University
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP